Blog barnaclínic


  1. 18 February, 2022

    The CAR-T ARI-0001 developed by the Hospital Clínic obtains the PRIME designation from the European Medicines Agency

    ARI-0001 is a CAR-T therapy that has been developed at Hospital Clínic for the treatment of acute lymphoblastic leukaemia. In February 2021, the Spanish Agency for Medicines and Health Products (AEMPS) approved its use and it became the first treatment with genetically modified cells and fully developed in Europe that was approved by a regulatory agency. The path of ARI-0001 has not stopped here, and now the European Medicines Agency (EMA) has granted it the PRIME designation, which means that it has become a priority for the agency thus offering its support for an evaluation acceleration of this therapy.

    Read more…

  2. 23 December, 2021

    The Hospital Clínic Group develops a second CAR-T, suitable for multiple myeloma resistant to treatment

    CAR-T para el Mieloma múltiple

    The Hospital Clínic Group of Barcelona along with the August Pi and Sunyer Biomedical Research Institute (IDIBAPS) have developed a new CAR-T, the ARI-0002h, for patients with multiple myeloma resistant to habitual treatments. The results of a clinical trial, recently presented in the American Society of Hematology (ASH), which was held in Atlanta, have demonstrated that this new CAR-T for multiple myeloma is capable of getting a response rate of up to 75% after a year of treatment and that in 60% of patients that have complete remission and without residual disease, results that are, without doubt, very hopeful.

    Read more…

  3. 16 February, 2021

    The AEMPS approves the use of a CAR-T therapy developed by the Hospital Clínic Group for the treatment of a type of leukaemia

    CAR-T ARI-0001 Inmunoterapia contra la leucemia

    In recent years, cancer treatment has been revolutionised by immunotherapy, an approach that uses a patient’s own immune system to attack tumour cells. The Spanish Agency of Medicines and Medical Devices (AEMPS) has just approved ARI-0001, a CAR T-cell therapy (a type of immunotherapy) developed entirely by the Hospital Clínic Group, for use as a medicinal product. This is the first time that a treatment with genetically modified cells developed entirely in Europe has been approved by a regulatory agency, and it is also the first time that it has been done without the backing of a pharmaceutical company.

    Read more…